SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Scribe Therapeutics to Present Updated PCSK9 and LPA Program Data

Scribe Therapeutics plans to present updated data on its PCSK9-targeting epigenetic silencing and LPA-targeting gene editing programs at the 2026 AHA Scientific Sessions.

SCTX

Related stories